Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 101–200 of 1,004
A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Mehran, R., Pocock, S. J., Nikolsky, E., Clayton, T., Dangas, G. D., Kirtane, A. J., Parise, H., Fahy, M., Manoukian, S. V., Feit, F., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.076 · Cited by 684
Cannon, C. P., Harrington, R. A., James, S., Ardissino, D., Becker, R. C., Emanuelsson, H., Husted, S., Katus, H., Keltai, M., Khurmi, N. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62191-7 · Cited by 664
Self-citationA Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907096 · Cited by 654
Windecker, S., Serruys, P. W., Wandel, S., Buszman, P., Trznadel, S., Linke, A., Lenk, K., Ischinger, T., Klauss, V., Eberli, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61244-1 · Cited by 653
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
Montalescot, G., Bolognese, L., Dudek, D., Goldstein, P., Hamm, C., Tanguay, J.-F., ten Berg, J. M., Miller, D. L., Costigan, T. M., Goedicke, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308075 · Cited by 657
Self-citationIntravenous Platelet Blockade with Cangrelor during PCI
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908629 · Cited by 648
Self-citationMega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.851949 · Cited by 651
Self-citationThe Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
“This study randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes to prasugrel or clopidogrel (Wiviott et al., 2007).”
BackgroundATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823a5596 · Cited by 632
Trenk, D., Stone, G. W., Gawaz, M., Kastrati, A., Angiolillo, D. J., Müller, U., Richardt, G., Jakubowski, J. A., & Neumann, F.-J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.026 · Cited by 626
“The low observed ischemic event rate in the control group even without correction of HTPR demonstrates that testing platelet function in such patients for consideration of more intensive antiplatelet therapy is not warranted, especially given the potentially increased risk of bleeding (13,14).”
BackgroundSelf-citationPlatelet Inhibition with Cangrelor in Patients Undergoing PCI
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908628 · Cited by 625
Self-citationSibbing, D., Aradi, D., Jacobshagen, C., Gross, L., Trenk, D., Geisler, T., Orban, M., Hadamitzky, M., Merkely, B., Kiss, R. G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32155-4 · Cited by 615
Self-citationWriting Committee Members, Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823b5fee · Cited by 614
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Walker, J. R., Simon, T., Antman, E. M., Braunwald, E., & Sabatine, M. S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61273-1 · Cited by 614
Self-citationUpdated Society for Vascular Surgery guidelines for management of extracranial carotid disease
Ricotta, J. J., AbuRahma, A., Ascher, E., Eskandari, M., Faries, P., & Lal, B. K. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.07.031 · Cited by 611
White, H. D., & Chew, D. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61237-4 · Cited by 588
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Kim, B.-K., Hong, S.-J., Cho, Y.-H., Yun, K. H., Kim, Y. H., Suh, Y., Cho, J. Y., Her, A.-Y., Cho, S., Jeon, D. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.7580 · Cited by 588
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Fox, K. A. A., Clayton, T. C., Damman, P., Pocock, S. J., de Winter, R. J., Tijssen, J. G. P., Lagerqvist, B., & Wallentin, L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.007 · Cited by 588
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Puymirat, E., Simon, T., Cayla, G., Cottin, Y., Elbaz, M., Coste, P., Lemesle, G., Motreff, P., Popovic, B., Khalife, K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030798 · Cited by 539
Sibbing, D., Aradi, D., Alexopoulos, D., ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., Gross, L., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.034 · Cited by 537
“Although this document expands on the recent findings from trials of deescalation, its intent is not to advocate for deescalation of P2Y12-inhibiting therapy routinely in clinical practice, where practitioners should abide, whenever possible, with guideline recommendations (29,32) on the choice of DAPT with highest le…”
BackgroundSelf-citationHeld, C., Åsenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., Harrington, R. A., Horrow, J., Husted, S., James, S. K., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.029 · Cited by 541
Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2526 · Cited by 519
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
“Thus, the ideal time to start, the optimal duration of treatment, and the balance between efficacy and safety with all these new anticoagulants remain to elucidate, especially in combination with new and more potent antiplatelet agents such as prasugrel and ticagrelor.(21,22) Notably, the phase III ACS trial with apix…”
BackgroundMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Gogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J. V., & Samama, C. M. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32833f6f6f · Cited by 529
Garg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 484
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Pagano, D., Milojevic, M., Meesters, M. I., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx325 · Cited by 481
Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.004 · Cited by 479
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P. (2011) · JAMA · doi:10.1001/jama.2011.1880 · Cited by 472
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Boer, C., Meesters, M. I., Milojevic, M., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.026 · Cited by 466
“tions is further reduced if a second-generation P2Y12 antagonist (ticagrelor/prasugrel) is used instead of clopidogrel [56, 57], but the risk of both spontaneous and surgical bleeding complications increases with the newer antagonists [56–58].”
BackgroundIbánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
APPRAISE Steering Committee and Investigators (2009) · Circulation · doi:10.1161/circulationaha.108.832139 · Cited by 461
Généreux, P., Giustino, G., Witzenbichler, B., Weisz, G., Stuckey, T. D., Rinaldi, M. J., Neumann, F.-J., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1323 · Cited by 454
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Wallentin, L., Varenhorst, C., James, S., Erlinge, D., Braun, O. O., Jakubowski, J. A., Sugidachi, A., Winters, K. J., & Siegbahn, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm545 · Cited by 457
Writing Committee Members, Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., et al. (2010) · Circulation · doi:10.1161/cir.0b013e318202f701 · Cited by 451
Self-citationWiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J.-P. R., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60422-5 · Cited by 453
Self-citationKulik, A., Ruel, M., Jneid, H., Ferguson, T. B., Hiratzka, L. F., Ikonomidis, J. S., Lopez-Jimenez, F., McNallan, S. M., Patel, M., Roger, V. L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000182 · Cited by 448
James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq325 · Cited by 446
Wang, L., Cong, H.-L., Zhang, J.-X., Hu, Y.-C., Wei, A., Zhang, Y.-Y., Yang, H., Ren, L.-B., Qi, W., Li, W.-Y., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01054-z · Cited by 435
Jennings, L. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0192 · Cited by 436
ST-segment elevation myocardial infarction
Vogel, B., Claessen, B. E., Arnold, S. V., Chan, D., Cohen, D. J., Giannitsis, E., Gibson, C. M., Goto, S., Katus, H. A., Kerneis, M., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0090-3 · Cited by 419
Self-citationWang, S. V., Schneeweiss, S., Initiative, R.-D., Franklin, J. M., Desai, R. J., Feldman, W., Garry, E. M., Glynn, R. J., Lin, K. J., Paik, J., et al. (2023) · JAMA · doi:10.1001/jama.2023.4221 · Cited by 428
Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention
Brar, S. S., ten Berg, J., Marcucci, R., Price, M. J., Valgimigli, M., Kim, H.-S., Patti, G., Breet, N. J., DiSciascio, G., Cuisset, T., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.059 · Cited by 422
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0224 · Cited by 418
Self-citationCuisset, T., Deharo, P., Quilici, J., Johnson, T. W., Deffarges, S., Bassez, C., Bonnet, G., Fourcade, L., Mouret, J. P., Lambert, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx175 · Cited by 414
Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., Delaney, J. T., Bowton, E., Brothers, K., Johnson, K., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.371 · Cited by 414
Antiplatelet therapies for the treatment of cardiovascular disease
Michelson, A. D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2957 · Cited by 407
“Results from the trial demonstrated that prasugrel (60 mg loading dose and a 10 mg daily maintenance dose), as compared with approved doses of clopidogrel (300 mg loading dose and a 75 mg daily maintenance dose), significantly reduced rates of ischaemic events, including stent thrombosis, but with an increased risk of…”
BackgroundValgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 409
Self-citationJames, S., Budaj, A., Aylward, P., Buck, K. K., Cannon, C. P., Cornel, J. H., Harrington, R. A., Horrow, J., Katus, H., Keltai, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.933796 · Cited by 407
Wallentin, L. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp296 · Cited by 409
James, S., Åkerblom, A., Cannon, C. P., Emanuelsson, H., Husted, S., Katus, H., Skene, A., Steg, P. G., Storey, R. F., Harrington, R., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.01.003 · Cited by 405
Farid, N. A., Kurihara, A., & Wrighton, S. A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009343005 · Cited by 397
“Although the target levels of ex vivo inhibition of platelet aggregation induced by ADP that produce clinically relevant effects by P2Y12 antagonists are unclear, the present clinical data indicate that greater degrees of inhibition of ADP-mediated platelet aggregation are associated with significant reduction in sten…”
BackgroundInternational Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031164 · Cited by 397
Self-citationAlexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.972323 · Cited by 396
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa-Uva*, M., Head, S. J., Milojevic, M., Collet, J.-P., Landoni, G., Castella, M., Dunning, J., Gudbjartsson, T., Linker, N. J., Sandoval, E., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 393
“if one of the more potent third-generation P2Y12 inhibitors (ticagrelor or prasugrel) is used instead of clopidogrel [36, 37], at the expense of increased spontaneous and surgical bleeding complications [36–38].”
BackgroundZulman, D. M., Sussman, J. B., Chen, X., Cigolle, C. T., Blaum, C. S., & Hayward, R. A. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1629-x · Cited by 394
Roberts, J. D., Wells, G. A., Le May, M. R., Labinaz, M., Glover, C., Froeschl, M., Dick, A., Marquis, J.-F., O'Brien, E., Goncalves, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 391
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 388
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr422 · Cited by 383
Mega, J. L., Hochholzer, W., Frelinger, A. L., Kluk, M. J., Angiolillo, D. J., Kereiakes, D. J., Isserman, S., Rogers, W. J., Ruff, C. T., Contant, C., et al. (2011) · JAMA · doi:10.1001/jama.2011.1703 · Cited by 383
Holmes, D. R., Kereiakes, D. J., Garg, S., Serruys, P. W., Dehmer, G. J., Ellis, S. G., Williams, D. O., Kimura, T., & Moliterno, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.016 · Cited by 367
Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31323-x · Cited by 380
Self-citationAcute Coronary Syndromes: Diagnosis and Management, Part I
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.10.917 · Cited by 377
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Ticagrelor in patients with stable coronary disease and diabetes
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908077 · Cited by 365
Aradi, D., Kirtane, A., Bonello, L., Gurbel, P. A., Tantry, U. S., Huber, K., Freynhofer, M. K., ten Berg, J., Janssen, P., Angiolillo, D. J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv104 · Cited by 367
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.057 · Cited by 366
“However, with the same LOE B (based on data from 2 large randomized trials) (12,13), in the 2017 ESC update, prasugrel or ticagrelor are given”
MethodFrelinger, A., Michelson, A., & Gremmel, T. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1564835 · Cited by 345
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
“6,7 Lipid-lowering therapies also have proven benefits for patients with AMI.”
BackgroundCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
“[79-82] In addition, the frequency of HLA-B*1502 is higher in South Asians, including Taiwanese, Hong Kong Chinese, Thai, and Indians (8-11%), than in North Asians, such as Beijing Chinese, Japanese, and Koreans (1-2%).”
BackgroundAn automated database case definition for serious bleeding related to oral anticoagulant use
Cunningham, A., Stein, C. M., Chung, C. P., Daugherty, J. R., Smalley, W. E., & Ray, W. A. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2109 · Cited by 359
“Indeed, the elevated incidence of serious bleeding for prasugrel may deter use of this newer drug in high-risk patients.(5) Thus, optimal clinical use of anti-clotting agents requires accurate information on the risk of serious bleeding complications.”
Background2011 Writing Group Members, Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820f2f3e · Cited by 357
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1109 · Cited by 352
Gimbel, M., Qaderdan, K., Willemsen, L., Hermanides, R., Bergmeijer, T., de Vrey, E., Heestermans, T., Tjon Joe Gin, M., Waalewijn, R., Hofma, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30325-1 · Cited by 357
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 354
Novel antiplatelet agents in acute coronary syndrome
Franchi, F., & Angiolillo, D. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.156 · Cited by 353
Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management
Olin, J. W., & Sealove, B. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0133 · Cited by 349
“Clopidogrel has been used as an alternative medication to aspirin in patients with PAD.(90,96,97) The efficacy of clopidogrel has been directly compared with that of aspirin in the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) trial.”
MethodSteg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., Leonardi, S., Liu, T., Skerjanec, S., Day, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61615-3 · Cited by 346
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.009 · Cited by 342
Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist
Husted, S., & Van Giezen, J. J. J. (2009) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00096.x · Cited by 339
“68) [29].”
Levine, G. N., Jeong, Y.-H., Goto, S., Anderson, J. L., Huo, Y., Mega, J. L., Taubert, K., & Smith, S. C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.104 · Cited by 337
Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 336
Saito, S., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1482 · Cited by 332
Valgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw525 · Cited by 330
Registry-based randomized clinical trials—a new clinical trial paradigm
James, S., Rao, S. V., & Granger, C. B. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.33 · Cited by 331
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_01 · Cited by 328
Self-citationWatanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5244 · Cited by 325
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.